Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | EphB2 |
| Gene Name: | EPHB2 |
| Protein Full Name: | Ephrin type-B receptor 2 |
| Alias: | CEK5; DRT; EC 2.7.10.1; EPH receptor B2; EPH3; EPH-3; EPHB2; Ephrin type-B receptor 2; EPHT3; EPTH3; ERK; HEK5; Kinase EphB2; NUK; Receptor protein-tyrosine kinase HEK5; SEK3; SEK-3; Tyro5 |
| Mass (Da): | 117493 |
| Number AA: | 1055 |
| UniProt ID: | P29323 |
| Locus ID: | 2048 |
| COSMIC ID: | EPHB2 |
| Gene location on chromosome: | 1p36.12 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 20499 |
| Percent of cancer specimens with mutations: | 1.22 |
| Normal role description: | EPHB2 is a receptor-tyrosine kinase that is activated upon binding ephrins. EPH receptors are widely expressed in early development and rarely detected in adult tissues. EPHB2 signalling has an important role in the development and structural organization of neurons. EPHB2 is also involved in angiogenesis, palate development and inner ear development through endolymph production. Defects in EPHB2 have been observed in the development of prostate cancer as well as prostate cancer cell lines which have originated from brain metastasis. EPHB2 has been suggested to act as a tumour suppressor protein. EPHB2 expression restricts the invasiveness of colorectal cancer cells into ephrin-B1 expressing cell populations, thus segregating cancer cells from normal cells. |
| Commentary on involvement of protein in cancer: | Less than 3% mutation in lung. |